{Reference Type}: Journal Article
{Title}: Tumor Infiltrating Effector Regulatory T Cells Express VEGF Receptor 2 in Patients With Colorectal Cancer.
{Author}: Tsumuraya H;Mimura K;Nakajima S;Hanayama H;Matsuishi A;Okayama H;Fukai S;Ito M;Ashizawa M;Chida S;Onozawa H;Sakamoto W;Saito M;Saze Z;Momma T;Kono K;
{Journal}: Anticancer Res
{Volume}: 44
{Issue}: 7
{Year}: 2024 Jul
{Factor}: 2.435
{DOI}: 10.21873/anticanres.17105
{Abstract}: <B>OBJECTIVE: </B>Regulatory T cells (Tregs) suppress various anti-tumor immune responses in the tumor microenvironment (TME) and their control is considered essential to enhancing efficacy of cancer immunotherapy. The purpose of the study was to evaluate the strategy to regulate Tregs through the vascular endothelial growth factor (VEGF) pathway.<BR><B>METHODS: </B>We evaluated VEGF receptor (VEGFR) expression in subtypes of Tregs by analysis of public databases and through flow cytometry by investigating surgically resected specimens and peripheral blood mononuclear cells (PBMCs) from 26 patients with advanced colorectal cancer (CRC).<BR><B>RESULTS: </B>Analysis of The Cancer Genome Atlas colorectal adenocarcinoma dataset (n=592) showed that mRNA expression of both FLT1 (VEGFR1) and KDR (VEGFR2) was positively correlated with mRNA expression of FOXP3 as well as Treg signature. Clinical specimens revealed abundant VEGFR2 expression on Tregs, but very marginal VEGFR1 expression. The frequency of effector Tregs, the most immunosuppressive fraction of Tregs, was significantly higher in the tumor than in the PBMC and normal mucosa, and the majority of effector Tregs expressed VEGFR2. Furthermore, by using in vitro generated Tregs, the proportion of Tregs expressing IL-10 or TGF-β1 was significantly inhibited by a VEGFR2 inhibitor.<BR><B>CONCLUSIONS: </B>A therapeutic strategy targeting the VEGFR2 axis may have a potential to control effector Tregs in the CRC-TME.